# PeLeMed

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pelemed

- Industry: Biotechnology
- Headquarters: Gwangju, South Korea
- Website: www.pelemed.com/
- Total disclosed funding: $6M
- Latest round: Series A (Dec 8, 2020)
- Investors on record: 6

## About

Founded in 2019 and based in Gwangju, South Korea, PeLeMed is a drug research and development company on cancer, nerve, immune diseases, and new drug development. In September 2026, PeLeMed raised KRW 5 billion in venture funding from new investors SGC Partners and GIST Holdings. Returning investor Samho Green Investment and other unspecified investors also participated in the round. The company will use the funding to advance the clinical development of its acute myeloid leukemia (AML) drug candidate, PLM-102, including its U.S. Phase I trial, and to accelerate research and development of additional oncology pipeline assets.

## Funding rounds

- Series A, Dec 8, 2020, $6M — KDB Capital, Samho Green Investment, Daekyo Investment, DT&Investment, Spring Camp, LSK Investment

## Investors

- KDB Capital (https://capitalatlas.ai/funds/kdb-capital) — Series A
- Samho Green Investment (https://capitalatlas.ai/funds/samho-green-investment) — Series A
- Daekyo Investment (https://capitalatlas.ai/funds/daekyo-investment) — Series A
- DT&Investment (https://capitalatlas.ai/funds/dt-investment) — Series A
- Spring Camp (https://capitalatlas.ai/funds/spring-camp) — Series A
- LSK Investment (https://capitalatlas.ai/funds/lsk-investment) — Series A